Symbols / CMMB $1.69 +1.87% Chemomab Therapeutics Ltd.

Healthcare • Biotechnology • Israel • NCM
CMMB Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Fundamentals
Scroll to Statements
Market Cap 12.17M Enterprise Value 962.03M Income -8.99M Sales — Book/sh 1.72 Cash/sh 0.02
Dividend Yield — Payout 0.00% Employees — IPO — P/E — Forward P/E -56.33
PEG — P/S — P/B 0.99 P/C — EV/EBITDA -101.30 EV/Sales —
Quick Ratio 7.14 Current Ratio 9.08 Debt/Eq — LT Debt/Eq — EPS (ttm) -1.44 EPS next Y -0.03
EPS Growth — Revenue Growth — Earnings 2026-03-19 ROA -38.86% ROE -69.54% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 7.20M Shs Float 507.24M Short Float 0.68%
Short Ratio 0.93 Short Interest — 52W High 5.88 52W Low 1.35 Beta 0.58 Avg Volume 69.59K
Volume 10.42K Target Price $15.00 Recom None Prev Close $1.66 Price $1.69 Change 1.87%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.00
Mean price target
2. Current target
$1.69
Latest analyst target
3. DCF / Fair value
$-20.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.69
Low
$5.00
High
$25.00
Mean
$15.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-27 main Oppenheimer Outperform → Outperform $25
2025-05-16 main Oppenheimer Outperform → Outperform $10
2025-02-20 main Maxim Group Buy → Buy $7
2024-11-15 reit Oppenheimer Outperform → Outperform $11
2024-05-13 init Maxim Group — → Buy $4
2024-05-06 up Oppenheimer Perform → Outperform $6
2024-03-08 main Oppenheimer Perform → Perform —
2023-10-06 init Roth MKM — → Buy $7
2023-06-07 down Oppenheimer Outperform → Perform —
2023-04-18 main Oppenheimer — → Outperform $7
2022-03-10 main Oppenheimer — → Outperform $20
2021-12-07 init Aegis Capital — → Buy $30
2021-05-26 init Cantor Fitzgerald — → Overweight $45
2021-05-07 init Oppenheimer — → Outperform $42
News
RSS: Latest CMMB news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
9.57
-35.09%
14.74
-42.11%
25.46
-10.77%
28.53
Research And Development
5.83
-48.50%
11.33
-38.38%
18.38
+8.27%
16.98
Selling General And Administration
3.73
+9.44%
3.41
-51.79%
7.08
-38.75%
11.56
General And Administrative Expense
3.73
+9.44%
3.41
-51.79%
7.08
-38.75%
11.56
Salaries And Wages
1.79
+13.19%
1.58
-59.22%
3.89
-39.54%
6.43
Other Gand A
1.38
+11.46%
1.24
-49.68%
2.46
-38.74%
4.02
Total Expenses
9.57
-35.09%
14.74
-42.11%
25.46
-10.77%
28.53
Operating Income
-9.57
+35.09%
-14.74
+42.11%
-25.46
+10.77%
-28.53
EBITDA
-9.50
+35.33%
-14.69
+42.16%
-25.39
+10.83%
-28.48
Normalized EBITDA
-9.50
+35.33%
-14.69
+42.16%
-25.39
+10.83%
-28.48
Reconciled Depreciation
0.07
+32.08%
0.05
-20.90%
0.07
+15.52%
0.06
EBIT
-9.57
+35.09%
-14.74
+42.11%
-25.46
+10.77%
-28.53
Net Income
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Pretax Income
-8.99
+35.50%
-13.95
+42.43%
-24.22
+14.05%
-28.18
Net Non Operating Interest Income Expense
0.57
-27.96%
0.79
-35.86%
1.24
+250.71%
0.35
Net Interest Income
0.57
-27.96%
0.79
-35.86%
1.24
+250.71%
0.35
Interest Income Non Operating
0.57
-27.96%
0.79
-35.86%
1.24
—
Interest Income
0.57
-27.96%
0.79
-35.86%
1.24
—
Tax Provision
0.00
0.00
0.00
+100.00%
-0.53
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Net Income From Continuing Operation Net Minority Interest
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Net Income From Continuing And Discontinued Operation
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Net Income Continuous Operations
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Normalized Income
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Net Income Common Stockholders
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Diluted EPS
-1.44
+58.14%
-3.44
+58.25%
-8.24
+14.88%
-9.68
Basic EPS
-1.44
+58.14%
-3.44
+58.25%
-8.24
+14.88%
-9.68
Basic Average Shares
6.38
+57.16%
4.06
+38.15%
2.94
+3.26%
2.84
Diluted Average Shares
6.38
+57.16%
4.06
+38.15%
2.94
+3.26%
2.84
Diluted NI Availto Com Stockholders
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Insurance And Claims
0.50
-7.25%
0.54
-16.98%
0.65
-40.22%
1.08
Rent And Landing Fees
0.06
+20.00%
0.05
-38.27%
0.08
+237.50%
0.02
Rent Expense Supplemental
0.06
+20.00%
0.05
-38.27%
0.08
+237.50%
0.02
Total Other Finance Cost
—
-0.79
+35.86%
-1.24
-250.71%
-0.35
Line Item Trend 2023-12-31 2022-12-31
Total Assets
22.15
-48.56%
43.06
Current Assets
20.90
-49.93%
41.74
Cash Cash Equivalents And Short Term Investments
19.78
-50.41%
39.89
Cash And Cash Equivalents
9.29
-31.27%
13.52
Other Short Term Investments
10.49
-60.22%
26.37
Receivables
0.29
-37.04%
0.46
Other Receivables
0.29
-37.04%
0.46
Prepaid Assets
0.75
-42.77%
1.31
Restricted Cash
0.08
-1.30%
0.08
Total Non Current Assets
1.25
-5.50%
1.33
Net PPE
0.69
+18.44%
0.58
Gross PPE
0.91
+21.74%
0.74
Accumulated Depreciation
-0.22
-33.35%
-0.17
Properties
0.00
0.00
Machinery Furniture Equipment
0.10
-1.94%
0.10
Construction In Progress
0.01
+0.00%
0.01
Other Properties
0.79
+26.52%
0.63
Leases
0.01
-12.50%
0.02
Goodwill And Other Intangible Assets
0.01
-42.71%
0.01
Other Intangible Assets
0.01
-42.71%
0.01
Investments And Advances
—
—
Other Investments
—
—
Non Current Prepaid Assets
0.56
-23.74%
0.73
Other Non Current Assets
—
—
Total Liabilities Net Minority Interest
5.15
-24.65%
6.84
Current Liabilities
4.84
-28.32%
6.75
Payables And Accrued Expenses
3.94
-22.25%
5.07
Payables
0.52
-69.43%
1.69
Accounts Payable
0.52
-69.43%
1.69
Current Accrued Expenses
3.42
+1.33%
3.38
Pensionand Other Post Retirement Benefit Plans Current
0.82
-47.24%
1.56
Current Debt And Capital Lease Obligation
0.08
-38.21%
0.12
Current Capital Lease Obligation
0.08
-38.21%
0.12
Total Non Current Liabilities Net Minority Interest
0.32
+247.25%
0.09
Long Term Debt And Capital Lease Obligation
0.32
+247.25%
0.09
Long Term Capital Lease Obligation
0.32
+247.25%
0.09
Stockholders Equity
17.00
-53.08%
36.22
Common Stock Equity
17.00
-53.08%
36.22
Capital Stock
0.00
0.00
Common Stock
0.00
0.00
Share Issued
284.09
+22.12%
232.64
Ordinary Shares Number
284.09
+28.55%
221.00
Treasury Shares Number
11.64
+0.00%
11.64
Additional Paid In Capital
105.67
+4.36%
101.26
Retained Earnings
-88.68
-38.95%
-63.82
Treasury Stock
0.00
-100.00%
1.22
Total Equity Gross Minority Interest
17.00
-53.08%
36.22
Total Capitalization
17.00
-53.08%
36.22
Working Capital
16.06
-54.10%
34.99
Invested Capital
17.00
-53.08%
36.22
Total Debt
0.39
+83.18%
0.21
Capital Lease Obligations
0.39
+83.18%
0.21
Net Tangible Assets
16.99
-53.08%
36.21
Tangible Book Value
16.99
-53.08%
36.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-11.13
+27.66%
-15.39
+34.84%
-23.61
-15.91%
-20.37
Cash Flow From Continuing Operating Activities
-11.13
+27.66%
-15.39
+34.84%
-23.61
-15.91%
-20.37
Net Income From Continuing Operations
-8.99
+35.50%
-13.95
+42.43%
-24.22
+12.39%
-27.65
Depreciation Amortization Depletion
0.07
+32.08%
0.05
-20.90%
0.07
+15.52%
0.06
Depreciation
0.07
+32.08%
0.05
-20.90%
0.07
+15.52%
0.06
Depreciation And Amortization
0.07
+32.08%
0.05
-20.90%
0.07
+15.52%
0.06
Other Non Cash Items
0.01
—
—
—
Stock Based Compensation
0.62
+0.97%
0.62
-58.62%
1.49
-53.57%
3.21
Change In Working Capital
-2.83
-34.30%
-2.11
-122.68%
-0.95
-123.66%
4.01
Change In Receivables
-1.14
-134.70%
-0.49
-153.93%
0.90
+1510.94%
-0.06
Change In Payables And Accrued Expense
-1.38
+22.09%
-1.77
-57.05%
-1.13
-135.50%
3.17
Change In Accrued Expense
-1.20
+36.30%
-1.89
-4293.33%
0.04
-98.41%
2.82
Change In Payable
-0.18
-251.28%
0.12
+109.98%
-1.17
-432.95%
0.35
Change In Account Payable
-0.18
-251.28%
0.12
+109.98%
-1.17
-432.95%
0.35
Change In Other Working Capital
-0.31
-314.38%
0.15
+120.17%
-0.72
-180.80%
0.90
Investing Cash Flow
5.39
+134.65%
2.30
-85.53%
15.88
-18.71%
19.53
Cash Flow From Continuing Investing Activities
5.39
+134.65%
2.30
-85.53%
15.88
-18.71%
19.53
Net PPE Purchase And Sale
-0.00
0.00
+100.00%
-0.00
+95.59%
-0.07
Purchase Of PPE
-0.00
0.00
+100.00%
-0.00
+95.59%
-0.07
Sale Of PPE
—
0.00
0.00
0.00
Capital Expenditure
-0.00
—
-0.00
+95.59%
-0.07
Net Investment Purchase And Sale
—
—
—
19.60
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
—
19.60
Net Other Investing Changes
5.39
+134.78%
2.30
-85.54%
15.88
-18.97%
19.60
Financing Cash Flow
7.16
-27.47%
9.87
+181.62%
3.50
+533.66%
-0.81
Cash Flow From Continuing Financing Activities
7.16
-27.47%
9.87
+181.62%
3.50
+533.66%
-0.81
Net Common Stock Issuance
7.14
-27.59%
9.87
+181.62%
3.50
+468.45%
-0.95
Common Stock Payments
—
0.00
0.00
+100.00%
-1.22
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-1.22
Proceeds From Stock Option Exercised
0.01
0.00
0.00
-100.00%
0.14
Net Other Financing Charges
—
—
—
—
Changes In Cash
1.42
+143.99%
-3.22
+23.82%
-4.23
-157.02%
-1.65
Beginning Cash Position
6.15
-34.38%
9.37
-31.10%
13.60
-10.79%
15.24
End Cash Position
7.56
+23.05%
6.15
-34.38%
9.37
-31.10%
13.60
Free Cash Flow
-11.13
+27.64%
-15.39
+34.84%
-23.61
-15.54%
-20.44
Income Tax Paid Supplemental Data
—
—
—
0.01
Common Stock Issuance
7.14
-27.59%
9.87
+181.62%
3.50
+1212.36%
0.27
Issuance Of Capital Stock
7.14
-27.59%
9.87
+181.62%
3.50
+1212.36%
0.27
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category